Trial Profile
I-ATTAC: Improved Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccines (Primary) ; Diphtheria-tetanus vaccine (Primary) ; Sargramostim (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- Acronyms I-ATTAC
- 07 Apr 2023 Status changed from suspended to discontinued.
- 07 Oct 2022 Planned End Date changed from 1 Aug 2028 to 1 Aug 2024.
- 07 Oct 2022 Planned primary completion date changed from 1 Aug 2028 to 1 Aug 2024.